These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity. Lin SXN; Ahring PK; Keramidas A; Liao VWY; Møller RS; Chebib M; Absalom NL Brain; 2024 Jan; 147(1):224-239. PubMed ID: 37647766 [TBL] [Abstract][Full Text] [Related]
3. Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Absalom NL; Liao VWY; Johannesen KMH; Gardella E; Jacobs J; Lesca G; Gokce-Samar Z; Arzimanoglou A; Zeidler S; Striano P; Meyer P; Benkel-Herrenbrueck I; Mero IL; Rummel J; Chebib M; Møller RS; Ahring PK Nat Commun; 2022 Apr; 13(1):1822. PubMed ID: 35383156 [TBL] [Abstract][Full Text] [Related]
4. Epileptic encephalopathy de novo GABRB mutations impair γ-aminobutyric acid type A receptor function. Janve VS; Hernandez CC; Verdier KM; Hu N; Macdonald RL Ann Neurol; 2016 May; 79(5):806-825. PubMed ID: 26950270 [TBL] [Abstract][Full Text] [Related]
5. GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy. Papandreou A; McTague A; Trump N; Ambegaonkar G; Ngoh A; Meyer E; Scott RH; Kurian MA Dev Med Child Neurol; 2016 Apr; 58(4):416-20. PubMed ID: 26645412 [TBL] [Abstract][Full Text] [Related]
11. De Novo Missense Variants in SLC32A1 Cause a Developmental and Epileptic Encephalopathy Due to Impaired GABAergic Neurotransmission. Platzer K; Sticht H; Bupp C; Ganapathi M; Pereira EM; Le Guyader G; Bilan F; Henderson LB; Lemke JR; Taschenberger H; Brose N; Abou Jamra R; Wojcik SM Ann Neurol; 2022 Dec; 92(6):958-973. PubMed ID: 36073542 [TBL] [Abstract][Full Text] [Related]
12. Molecular and clinical descriptions of patients with GABA Maillard PY; Baer S; Schaefer É; Desnous B; Villeneuve N; Lépine A; Fabre A; Lacoste C; El Chehadeh S; Piton A; Porter LF; Perriard C; Wardé MA; Spitz MA; Laugel V; Lesca G; Putoux A; Ville D; Mignot C; Héron D; Nabbout R; Barcia G; Rio M; Roubertie A; Meyer P; Paquis-Flucklinger V; Patat O; Lefranc J; Gerard M; ; de Bellescize J; Villard L; De Saint Martin A; Milh M Epilepsia; 2022 Oct; 63(10):2519-2533. PubMed ID: 35718920 [TBL] [Abstract][Full Text] [Related]
14. Phenotype Expression Variability in Children with GABRB3 Heterozygous Mutations. Khair AM; Salvucci AE Oman Med J; 2021 Mar; 36(2):e240. PubMed ID: 33854792 [No Abstract] [Full Text] [Related]
15. Epiberberine induced p53/p21-dependent G2/M cell cycle arrest and cell apoptosis in gastric cancer cells by activating γ-aminobutyric acid receptor- β3. Li M; Yang J; Li J; Zhou Y; Li X; Ma Z; Li X; Ma H; Ye X Phytomedicine; 2024 Jan; 123():155198. PubMed ID: 38006806 [TBL] [Abstract][Full Text] [Related]
16. GABA and epileptogenesis: comparing gabrb3 gene-deficient mice with Angelman syndrome in man. DeLorey TM; Olsen RW Epilepsy Res; 1999 Sep; 36(2-3):123-32. PubMed ID: 10515160 [TBL] [Abstract][Full Text] [Related]
17. Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report. Zhang Y; Lian Y; Xie N Medicine (Baltimore); 2017 Dec; 96(50):e9273. PubMed ID: 29390378 [TBL] [Abstract][Full Text] [Related]